US2155658A - Surgical and medical preparations - Google Patents
Surgical and medical preparations Download PDFInfo
- Publication number
- US2155658A US2155658A US118088A US11808836A US2155658A US 2155658 A US2155658 A US 2155658A US 118088 A US118088 A US 118088A US 11808836 A US11808836 A US 11808836A US 2155658 A US2155658 A US 2155658A
- Authority
- US
- United States
- Prior art keywords
- parts
- surgical
- weight
- polymerized vinyl
- fillings
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title description 15
- 239000000463 material Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- -1 vinyl alcohols Chemical class 0.000 description 14
- 235000015110 jellies Nutrition 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 9
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 7
- BBNQQADTFFCFGB-UHFFFAOYSA-N Purpurin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011049 filling Methods 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000008023 solidification Effects 0.000 description 7
- 238000007711 solidification Methods 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940039231 contrast media Drugs 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000001370 mediastinum Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002737 metalloid compounds Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000003175 thyreotropic effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S260/00—Chemistry of carbon compounds
- Y10S260/47—Poisons, foods, or pharmaceuticals
Definitions
- This invention relates to surgicaland medical preparations and has for its object the production of improved materials for insertion, infusion or injection into the human or animal system for their desirable therapeutic or cosmetic effects, or for use as plastic fillings, joint lubricants and other surgical purposes.
- medical deposits may be introduced into the tissues as a substitute for the usual method of making frequent injections of dissolved medicines. Similar deposits may be made for the purpose of introducing disinfectants, cosmetics, contrast media and anaesthetics into the body.
- An important advantage of the invention is that the effect of such deposits, whether for surgical or medical purposes, may be localized in any given regionof the body; for example, by the infusion of a suitable deposit in lumbar anaesthesia, a localized efiect of the anaesthetic contained in the deposit may be obtained.
- Plastic fillings made according to our invention may be used wherever cavities are to be filled in the body.
- lumbar fillings may be introduced after the resection or pathological destruction of parts of the lungs.
- bone fillings may be inserted, paste-like joint greases introduced and the like.
- our invention provide improved materials for these and other surgical and medical purposes, but' it furthermore extends the field of application of such materials to a wide variety of purposes not contemplated in the prior art.
- gland preparations et c., anaesthetics, disinfectants, contrast media and cosmetics. Their excellent suitability as vehicles for iodine, iodoform and other iodine preparations is particularly important.
- these polymerized vinyl compounds may be treated to form solutions, jellies, pastes or powders adapted merely to swell up with solvents, or kneadable masses, with surprising deftness and with such exactness in their qualities as to meet the requirements of medicine and surgery from the standpoint of the patient as Well as the physician, with the result that the desired final condition is attained with precision and entirely new fields 01' application are made possible.
- the purpose is to effect an accurately graded conversion of fiowable materials into thinner or thicker solutions, Jellies and pastes and, finally, into solid, rigid masses with a higher or lower softening point, of lower or higher iusibility; or to render paste-like masses more gelatinous to flowable, or even to liquefy them.
- This modification may be effected by means of physical or chemical (or colloidal chemical) reactions or a combination of the two.
- physical agencies for instance irradiation, but particularly by means of thermal treatment, the complexion of the colloidal properties of the solutions, pastes, etc., may be changed in the direction which is characterized by an increase of viscosity in the sense indicated above.
- metal compounds such as chromium,
- iron and aluminum salts which have a tanning eflect
- soluble salts of organic acids such as acetates, particularly sodium acetate
- metalloidcompounds which have a tanning effect, such as boric acid and borates, are also effective.
- Congo red is much more efiective than benzo purpurin; accordingly, by using a suitable quantity of benzo purpurin instead of Congo red, in a mass which is non-adhesive and which solidifies at body temperature,
- low concentrated-solutions, jellies, pastes or plastic masses may be given the solidity characteristics of highly concentrated, relatively insoluble substances.
- deposits, fillings, etc. which are made solid-for some definite purpose, can be introduced into the body with the incorporation of a disproportionately small quantity of a substance foreign to the body.
- An important advantage of our invention is that it enables infusion masses, deposits of medicaments, plastic fillings, stiffening means and the like to be produced with great exactness; it makes it possible to produce materials of this type which can be readily injected into the body at moderate temperatures, for instance 40-44? C. 'in liquid form, and which solidify in the body in accordance with the intended purpose at its temperature range of 36-42 C. and thus localized themselves or permit themselves to be distributed more or less diffused as desired. In this way rib resections, for example in the filling of lung cavities, become unnecessary and are replaced by a simple injection.
- Our invention also results in a revolutionary improvement in the case of lung operations which heretofore have had to be performed at low or high pressure.
- it is no longer necessary in opening the thorax to prevent the dangerous bending over of the mediastinum by artificially influencing pressure relations or conditions, because polymerized vinyl compounds produced according to our invention may be soadjusted that they can be injected into the mediastinum in liquid form and there solidify and thus act as stifi'eners so that bending over during the operation is prevented.
- This surprisingly advantageous application of these compounds as stifleners in surgical and medical cases is considered to be a particularly valuable feature of the invention.
- Example 1 A solution of the consistency of honey, composed of 30 parts by weight of medium viscous polymerized vinyl alcohol and parts by weight of water, is converted into a homogeneous jelly by heating for 48 hours to a temperature of 120 C. in a closed glass jar.
- the resulting product is exceptionally well suited, for example, for filling up cavities in the body or as a joint lubricant.
- reabsorbability it may be effected by the addition of resorption promot ing substances, particularlyorganic acids such as lactic acid or acetic acid.
- Example 2 A gum-dry non-homogeneous mixture produced from 60 parts by weight of highly polymerized vinyl alcohol and 90 parts by weight of water is converted by heating for a period of 8 days to 100 C. in a closed bell jar into a homogeneous elastic mass which is gum-like when cold and which becomes soft under heat. This mass also produces good plastic fillings.
- Example 3 1000 parts by weight of a readily fiowable aqueous solution of 10% strength of medium viscous polymerized vinyl alcohol are mixed with 2 parts of sodium acetate. This produces a clear, homogeneous, thin jelly, which serves as a plastic filling, a vehicle for deposits of medicaments, and as infusion masses.
- Example 4 1000 parts by weight of a solution of highly viscous polymerized vinyl alcohol in water, of
- Example 6 If the procedure of Example 5 is followed, with the substitution of benzo purpurln for the Congo red, a jelly of lower consistency is obtained.
- Example 7 1000 parts by weight of an aqueous solution of highly polymerized vinyl alcohol of 6% strength are hardened, by the addition of 3 parts by weight of benzo purpurin, to a jelly with a jelliflcation point of 27-28 C. a 1
- Example 8 If, in carrying out the process ,of Example 7. the benzo purpurin is replaced by the same quantity of Congo red, the viscous solution solidifies to a rigid mass with a solidification point of 42 C. This mass may be liquefied by heating. It maintains this condition on cooling until it can be injected into the body with an injection syringe, for instance as solidification means into the niediastinuni.
- Example 9 1000 parts by weight of an aqueous solution of polymerized vinyl alcohol of 7% strength are mixed with 4.2 parts by weight of benzo purpurin. The resulting product is a jelly with a jellification point of 39.5" C., which adheres to serous glands or membranes and other body parts in the form of plastic fillings or deposits for there.-
- Example 10 If in the process of Example 9 the 4.2 parts by weight of benzo purpurin are replaced by 3.5 parts by weight of Congo red, there is obtained a rigid mass with a solidification point of 43-44 C., which does not adhere to serous glands or membranes or other body parts. It is suited, for example, for plastic fillings which are to rest in a body pocket in a manner capable of moving.
- Example 11 A solution of polymerized vinyl alcohol in water, of 8.75% strength, is solidified with the addition of 4.4 parts by weight of Congo red to 1000 parts by weight of said solution, to a mass with a solidification point of 44 C.
- a quantity of 4 cu. cm. of this mass is mixed, after sterilization by heating to 120 C. for one-half hour, with 1 cu. cm. of sterile hydrochloric acid of 1% normal strength with a common salt content of 7 parts in 1000 parts and 200 guinea pig units of thyreotropic hormone.
- This mixture has a solidification point of 42-43 C., can be injected into the body upon heating to 44-45 C. by means of a standard injection syringe, and solidifies in the body.
- a surgical and medical preparation for injection into body cavities in the human and animal system comprising a mixture containing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives, and a solvent for such material, said preparation being capable of being rendered fiowable for ready injection into the body at temperatures above body temperature and which is not injurious to the body and becoming solid at body temperature after injection.
- a surgical and medical preparation for injection into body cavities in the human and animal system comprising a mixture containing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives, and a solvent for such material, said preparation containing an organic dyestufi' selected from the group consisting of Congo red and benzo purpurin in a quantity sumcient to make said preparation capable of being rendered flowable for ready injection into the body at temperatures above body temperature and which is not injurious to the body and becoming solid at body temperature after inlection.
- a process of manufacturing surgical and medical preparations for injection into body cavities in the human and animal system comprising mixing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives with a
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Patented Apr. 25, 1939 v UNITED. STATES PATENT OFFICE 2,155,858 suaorcu. AND MEDICAL PREPARATIONS poration of Germany No Drawing. Application December 29,1938, Se-
rial No. 118,088. In Germany January 8.
This invention relates to surgicaland medical preparations and has for its object the production of improved materials for insertion, infusion or injection into the human or animal system for their desirable therapeutic or cosmetic effects, or for use as plastic fillings, joint lubricants and other surgical purposes.
By means of our preparations, for example, medical deposits may be introduced into the tissues as a substitute for the usual method of making frequent injections of dissolved medicines. Similar deposits may be made for the purpose of introducing disinfectants, cosmetics, contrast media and anaesthetics into the body. An important advantage of the invention is that the effect of such deposits, whether for surgical or medical purposes, may be localized in any given regionof the body; for example, by the infusion of a suitable deposit in lumbar anaesthesia, a localized efiect of the anaesthetic contained in the deposit may be obtained.
Plastic fillings made according to our invention may be used wherever cavities are to be filled in the body. For example, lumbar fillings may be introduced after the resection or pathological destruction of parts of the lungs. Likewise, bone fillings may be inserted, paste-like joint greases introduced and the like. Not only does our invention provide improved materials for these and other surgical and medical purposes, but' it furthermore extends the field of application of such materials to a wide variety of purposes not contemplated in the prior art.
Fillings and deposits for some of the purposes mentioned above have been manufactured from parafllne, stearic acids, waxes and the like, but they have met with only indifferent success. One disadvantage of such materials is that they. have an irritating eifect upon the environment and are treated as foreign bodies. Another disadvantage is that they can be sterilized only by means of additions which have a bactericidal effect, but which thereby aggravate the irritation and are furthermore not resorptive. Moreover, previously known materials of this type are very diflicult to apply, and it is impossible accurately to adjust their viscosity, plasticity and other colloidal properties to medical and surgical requirements.
We have discovered certain novel preparations which can be adapted to the above surgical and medical purp'oses with the greatest accuracy and which, furthermore, are entirely free from the disadvantages of other deposit and filling mathe viscosity of the product.
:i Claims. (Cl. 167-58) terials. These novel preparations are polymerized vinyl alcohols of various viscosities, and
their esters, acetals and ethers as well as esteracetals and mixtures of such compounds, in so far as, they have an appreciable solubility in water, which requirement is met in certain cases if the preparations are capable of swelling inwater. These polymerized vinyl compounds are particularly well suited for the above purpose because they do not exercise any irritating effect upon living tissues but are tolerated in any quantity without any reaction; they can be made absolutely sterile without the addition of bactericidal substances because they can stand heating up to 130-140 C. without injury to their properties; and by means of suitable additions, preferably electrolytes and particularly organic acids such as lactic acid, acetic acid and the like, they can be made reabsorbable to any desired degree. Moreover, they are distinguished by an extraordinary compatibility with the most varied medicaments, for instance alkaloids, cardiacs,
gland preparations, et c., anaesthetics, disinfectants, contrast media and cosmetics. Their excellent suitability as vehicles for iodine, iodoform and other iodine preparations is particularly important. In addition, these polymerized vinyl compounds may be treated to form solutions, jellies, pastes or powders adapted merely to swell up with solvents, or kneadable masses, with surprising deftness and with such exactness in their qualities as to meet the requirements of medicine and surgery from the standpoint of the patient as Well as the physician, with the result that the desired final condition is attained with precision and entirely new fields 01' application are made possible.
The foregoing desirable results are obtained by treating the said solutions, jellies, pastes, swollen masses, etc., with solvents such as, for example, glycols, glycerine, formamid, and particularly water, which alter the colloidal properties of these more or less homogeneous mixtures in a manner dictated by thepurposes to which the products are to be applied. The most important characteristic of this change is an alteration of For example it causes more or less free flowing solutions to thicken, gelatinize or become more solid; it causes a further thickening or solidification of jellies; an increase of solidity of pastes; a rigidifying or toughening of plastic masses. In general the purpose is to effect an accurately graded conversion of fiowable materials into thinner or thicker solutions, Jellies and pastes and, finally, into solid, rigid masses with a higher or lower softening point, of lower or higher iusibility; or to render paste-like masses more gelatinous to flowable, or even to liquefy them. This modification may be effected by means of physical or chemical (or colloidal chemical) reactions or a combination of the two. By the action of physical agencies, for instance irradiation, but particularly by means of thermal treatment, the complexion of the colloidal properties of the solutions, pastes, etc., may be changed in the direction which is characterized by an increase of viscosity in the sense indicated above.
If the solutions, pastes, etc., are subjected to the reaction of substances which tend to solidify them, a modification of the colloidal properties in the same direction is effected. Substances which operate to produce a solidifying effect are,
for example, metal compounds such as chromium,
iron and aluminum salts, which have a tanning eflect; also soluble salts of organic acids such as acetates, particularly sodium acetate; and metalloidcompounds which have a tanning effect, such as boric acid and borates, are also effective. A
specific effect in this direction is had by the univalent and polyvalent alcohols, such, for instance, as ethyl alcohol and glycerine; their capacity to absorb water-effects or promotes in a special manner the solidification of the colloids discussed here. Organic dyestuffs of the Congo red and benzo purpurin class as well as other dyestuffs having an equivalent reaction upon colloids are particularly active in this connection.
As a general rule they act in very small concen- 5 By way of example, Congo red is much more efiective than benzo purpurin; accordingly, by using a suitable quantity of benzo purpurin instead of Congo red, in a mass which is non-adhesive and which solidifies at body temperature,
it is possible to obtain a strongly adhesive substance. There are many situations in which this possibility of modification is important: for example in filling cavities in the upper part of the lung it enables us to make the inserted filling adhere strongly to the surface of the cavity so that it will not drop down during breathing; likewise, for segmentary localized lumbar anaesthesia we can produce a deposit material with suitable adhesive capacity together with other so specific properties such as light weight and the capacity to become solid in the body. In other cases it is desirable to make the fillings lie, as far as possible without adhesion in a pocket-like cavity, and fillings for this purpose can also be produced in accordance with our invention.
By meansof appropriate physical or colloidalchemical solidifying methods or combinations of such methods, low concentrated-solutions, jellies, pastes or plastic masses may be given the solidity characteristics of highly concentrated, relatively insoluble substances. In this way, for example, deposits, fillings, etc., which are made solid-for some definite purpose, can be introduced into the body with the incorporation of a disproportionately small quantity of a substance foreign to the body. In certain cases on the other hand, it is desirable to obtain highly concentrated fillings and the like which are as compact as possible, and in such cases concentrated solutions, jellies, pastes or plastic masses may be used and the consistency required for the simplest and best meth- 0d of incorporation into the body may be effected by reducing the viscosity. This may also be accomplished according to our invention by influencing the colloidal propertiesof the mixtures of the above-mentioned polymerized vinyl compounds with solvents, particularly water. For this purpose organic acids, for example lactic acids, tartaric acid, acetic acid and the like may be incorporated in the solutions, pastes, etc. By appropriate selection and proportioning of. the ingredients and suitable treatment of the mixture highly concentrated materials can be introduced into the body in abnormally thin and free flowing condition, these materials only gradually assuming the desired final consistency in the body as a result of the extraction by lixiviation of the lactic acid and the like.
An important advantage of our invention, as illustrated by the examples hereinafter given, is that it enables infusion masses, deposits of medicaments, plastic fillings, stiffening means and the like to be produced with great exactness; it makes it possible to produce materials of this type which can be readily injected into the body at moderate temperatures, for instance 40-44? C. 'in liquid form, and which solidify in the body in accordance with the intended purpose at its temperature range of 36-42 C. and thus localized themselves or permit themselves to be distributed more or less diffused as desired. In this way rib resections, for example in the filling of lung cavities, become unnecessary and are replaced by a simple injection. Our invention also results in a revolutionary improvement in the case of lung operations which heretofore have had to be performed at low or high pressure. As a result of our invention it is no longer necessary in opening the thorax to prevent the dangerous bending over of the mediastinum by artificially influencing pressure relations or conditions, because polymerized vinyl compounds produced according to our invention may be soadjusted that they can be injected into the mediastinum in liquid form and there solidify and thus act as stifi'eners so that bending over during the operation is prevented. This surprisingly advantageous application of these compounds as stifleners in surgical and medical cases is considered to be a particularly valuable feature of the invention.
The following examples are given for the purpose of illustrating the invention without limiting it in any way to the specificconditions, concentrations, etc., which are used: 4
Example 1 A solution of the consistency of honey, composed of 30 parts by weight of medium viscous polymerized vinyl alcohol and parts by weight of water, is converted into a homogeneous jelly by heating for 48 hours to a temperature of 120 C. in a closed glass jar. The resulting product is exceptionally well suited, for example, for filling up cavities in the body or as a joint lubricant. In case reabsorbability is required, it may be effected by the addition of resorption promot ing substances, particularlyorganic acids such as lactic acid or acetic acid.
Example 2 A gum-dry non-homogeneous mixture produced from 60 parts by weight of highly polymerized vinyl alcohol and 90 parts by weight of water is converted by heating for a period of 8 days to 100 C. in a closed bell jar into a homogeneous elastic mass which is gum-like when cold and which becomes soft under heat. This mass also produces good plastic fillings.
Example 3 1000 parts by weight of a readily fiowable aqueous solution of 10% strength of medium viscous polymerized vinyl alcohol are mixed with 2 parts of sodium acetate. This produces a clear, homogeneous, thin jelly, which serves as a plastic filling, a vehicle for deposits of medicaments, and as infusion masses.
Example 4 Example 5 1000 parts by weight of a solution of highly viscous polymerized vinyl alcohol in water, of
6% strength, which is a readily flowable liquid,-
are mixed with 2 parts by weight of Congo red. As a result jellification occurs in the course of a few hours and the point of softening is increased to about 35 C. This mass is suitable as a base for deposits of all kinds and as plastic filling.
Example 6 If the procedure of Example 5 is followed, with the substitution of benzo purpurln for the Congo red, a jelly of lower consistency is obtained.
Example 7 1000 parts by weight of an aqueous solution of highly polymerized vinyl alcohol of 6% strength are hardened, by the addition of 3 parts by weight of benzo purpurin, to a jelly with a jelliflcation point of 27-28 C. a 1
Example 8 If, in carrying out the process ,of Example 7. the benzo purpurin is replaced by the same quantity of Congo red, the viscous solution solidifies to a rigid mass with a solidification point of 42 C. This mass may be liquefied by heating. It maintains this condition on cooling until it can be injected into the body with an injection syringe, for instance as solidification means into the niediastinuni.
Example 9 1000 parts by weight of an aqueous solution of polymerized vinyl alcohol of 7% strength are mixed with 4.2 parts by weight of benzo purpurin. The resulting product is a jelly with a jellification point of 39.5" C., which adheres to serous glands or membranes and other body parts in the form of plastic fillings or deposits for there.-
75 D utically effective substances.
Example 10 If in the process of Example 9 the 4.2 parts by weight of benzo purpurin are replaced by 3.5 parts by weight of Congo red, there is obtained a rigid mass with a solidification point of 43-44 C., which does not adhere to serous glands or membranes or other body parts. It is suited, for example, for plastic fillings which are to rest in a body pocket in a manner capable of moving.
Example 11 A solution of polymerized vinyl alcohol in water, of 8.75% strength, is solidified with the addition of 4.4 parts by weight of Congo red to 1000 parts by weight of said solution, to a mass with a solidification point of 44 C. A quantity of 4 cu. cm. of this mass is mixed, after sterilization by heating to 120 C. for one-half hour, with 1 cu. cm. of sterile hydrochloric acid of 1% normal strength with a common salt content of 7 parts in 1000 parts and 200 guinea pig units of thyreotropic hormone. This mixture has a solidification point of 42-43 C., can be injected into the body upon heating to 44-45 C. by means of a standard injection syringe, and solidifies in the body.
It will be evident that many changes may be made in the processes and products described above without departing from the scope and spirit of the invention as defined in the appended claims.
The invention claimed is: v I
1. A surgical and medical preparation for injection into body cavities in the human and animal system comprising a mixture containing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives, and a solvent for such material, said preparation being capable of being rendered fiowable for ready injection into the body at temperatures above body temperature and which is not injurious to the body and becoming solid at body temperature after injection.
2. A surgical and medical preparation for injection into body cavities in the human and animal system comprising a mixture containing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives, and a solvent for such material, said preparation containing an organic dyestufi' selected from the group consisting of Congo red and benzo purpurin in a quantity sumcient to make said preparation capable of being rendered flowable for ready injection into the body at temperatures above body temperature and which is not injurious to the body and becoming solid at body temperature after inlection.
3. A process of manufacturing surgical and medical preparations for injection into body cavities in the human and animal system comprising mixing at least one material selected from the group consisting of polymerized vinyl alcohols and their water soluble derivatives with a
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2155658X | 1936-01-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2155658A true US2155658A (en) | 1939-04-25 |
Family
ID=7987651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US118088A Expired - Lifetime US2155658A (en) | 1936-01-08 | 1936-12-29 | Surgical and medical preparations |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US2155658A (en) |
Cited By (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2467583A (en) * | 1945-04-17 | 1949-04-19 | Rhone Poulenc Sa | Penicillin solutions |
| US2477292A (en) * | 1946-10-11 | 1949-07-26 | Wyeth Corp | Polyvinyl-alcohol-coated suppository |
| US2486937A (en) * | 1947-07-09 | 1949-11-01 | Jr Edgar A Ferguson | Digitalis therapy |
| US2693438A (en) * | 1951-02-21 | 1954-11-02 | Norwich Pharma Co | Preformed, nonadherent films for application to open lesions |
| US2903396A (en) * | 1957-05-08 | 1959-09-08 | Ciba Pharm Prod Inc | Therapeutic compositions and method for treating parkinsonism |
| US2935472A (en) * | 1954-08-16 | 1960-05-03 | Minnesota Mining & Mfg | Lost circulation materials |
| US3236735A (en) * | 1962-09-14 | 1966-02-22 | Mallinckrodt Chemical Works | Barium sulfate and low viscosity monosaccharide polymer x-ray contrast media |
| US3247841A (en) * | 1961-05-29 | 1966-04-26 | Galen B Cook | Diagnostic method |
| US3313292A (en) * | 1965-06-24 | 1967-04-11 | Galen B Cook | Diagnostic composition package |
| US3317394A (en) * | 1955-12-22 | 1967-05-02 | Haessle Ab | Medicinal tablet and a method for its preparation |
| US3492250A (en) * | 1963-05-21 | 1970-01-27 | Du Pont | Closed cell foam |
| US3967922A (en) * | 1973-08-16 | 1976-07-06 | Bayer Aktiengesellschaft | Granular dyestuff preparations based on polyvinylalcohol as the carrier |
| US4200939A (en) * | 1977-10-19 | 1980-05-06 | Codman & Shurtleff, Inc. | Method for fixation of prostheses to bone |
| US4265875A (en) * | 1976-07-23 | 1981-05-05 | Inveresk Research International | Controlled release suppositories |
| US4296097A (en) * | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
| US4302480A (en) * | 1978-06-16 | 1981-11-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thin cover sheet for use in microscopic staining and a process for its production |
| US4342745A (en) * | 1979-05-31 | 1982-08-03 | Zyma S.A. | Use of polyvinyl alcohols for the treatment of lesions |
| WO1983000092A1 (en) * | 1981-07-08 | 1983-01-20 | Key Pharma | Polymeric diffusion matrix containing propranolol |
| WO1983000091A1 (en) * | 1981-07-08 | 1983-01-20 | Keith, Alec, Dell | Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile |
| WO1983000093A1 (en) * | 1981-07-08 | 1983-01-20 | Key Pharma | Trinitroglycerol sustained release vehicles and preparation therefrom |
| US4430260A (en) | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
| US4438139A (en) | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
| US4460562A (en) * | 1982-01-06 | 1984-07-17 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US4466953A (en) * | 1979-08-14 | 1984-08-21 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix |
| US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US5278201A (en) * | 1988-10-03 | 1994-01-11 | Atrix Laboratories, Inc. | Biodegradable in-situ forming implants and methods of producing the same |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| US5632727A (en) * | 1988-10-03 | 1997-05-27 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
| US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
| US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5707647A (en) * | 1994-04-08 | 1998-01-13 | Atrix Laboratories, Inc. | Adjunctive polymer system for use with medical device |
| US5722950A (en) * | 1995-06-07 | 1998-03-03 | Atrix Laboratories, Inc. | Method for remote delivery of an aerosolized liquid |
| US5744153A (en) * | 1994-04-08 | 1998-04-28 | Atrix Laboratories, Inc. | Liquid delivery compositions |
| US5792469A (en) * | 1992-03-12 | 1998-08-11 | Atrix Laboratories, Inc. | Biodegradable in situ forming film dressing |
| US5945115A (en) * | 1991-10-15 | 1999-08-31 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US6083524A (en) * | 1996-09-23 | 2000-07-04 | Focal, Inc. | Polymerizable biodegradable polymers including carbonate or dioxanone linkages |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040127846A1 (en) * | 1999-09-24 | 2004-07-01 | Dunn Richard L. | Coupling syringe system and methods for obtaining a mixed composition |
| US20040156781A1 (en) * | 2002-10-15 | 2004-08-12 | Porter Christopher H. | Polymeric materials for site specific delivery to the body |
| US20050118242A1 (en) * | 2000-08-30 | 2005-06-02 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US20050152956A1 (en) * | 2000-08-30 | 2005-07-14 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US7128927B1 (en) | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| US8466138B2 (en) | 2005-10-12 | 2013-06-18 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| WO2022155430A1 (en) * | 2021-01-15 | 2022-07-21 | Athena Devices, Inc. | Compositions and methods for soft tissue augmentation |
-
1936
- 1936-12-29 US US118088A patent/US2155658A/en not_active Expired - Lifetime
Cited By (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2467583A (en) * | 1945-04-17 | 1949-04-19 | Rhone Poulenc Sa | Penicillin solutions |
| US2477292A (en) * | 1946-10-11 | 1949-07-26 | Wyeth Corp | Polyvinyl-alcohol-coated suppository |
| US2486937A (en) * | 1947-07-09 | 1949-11-01 | Jr Edgar A Ferguson | Digitalis therapy |
| US2693438A (en) * | 1951-02-21 | 1954-11-02 | Norwich Pharma Co | Preformed, nonadherent films for application to open lesions |
| US2935472A (en) * | 1954-08-16 | 1960-05-03 | Minnesota Mining & Mfg | Lost circulation materials |
| US3317394A (en) * | 1955-12-22 | 1967-05-02 | Haessle Ab | Medicinal tablet and a method for its preparation |
| US2903396A (en) * | 1957-05-08 | 1959-09-08 | Ciba Pharm Prod Inc | Therapeutic compositions and method for treating parkinsonism |
| US3247841A (en) * | 1961-05-29 | 1966-04-26 | Galen B Cook | Diagnostic method |
| US3236735A (en) * | 1962-09-14 | 1966-02-22 | Mallinckrodt Chemical Works | Barium sulfate and low viscosity monosaccharide polymer x-ray contrast media |
| US3492250A (en) * | 1963-05-21 | 1970-01-27 | Du Pont | Closed cell foam |
| US3313292A (en) * | 1965-06-24 | 1967-04-11 | Galen B Cook | Diagnostic composition package |
| US3967922A (en) * | 1973-08-16 | 1976-07-06 | Bayer Aktiengesellschaft | Granular dyestuff preparations based on polyvinylalcohol as the carrier |
| US4265875A (en) * | 1976-07-23 | 1981-05-05 | Inveresk Research International | Controlled release suppositories |
| US4292300A (en) * | 1976-07-23 | 1981-09-29 | Inveresk Research International | Controlled release suppositories |
| US4200939A (en) * | 1977-10-19 | 1980-05-06 | Codman & Shurtleff, Inc. | Method for fixation of prostheses to bone |
| US4302480A (en) * | 1978-06-16 | 1981-11-24 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Thin cover sheet for use in microscopic staining and a process for its production |
| US4296097A (en) * | 1979-02-27 | 1981-10-20 | Lee Weng Y | Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor |
| US4430260A (en) | 1979-02-27 | 1984-02-07 | Lee Weng Y | Penicillin-polyvinyl alcohol conjugate and process of preparation |
| US4342745A (en) * | 1979-05-31 | 1982-08-03 | Zyma S.A. | Use of polyvinyl alcohols for the treatment of lesions |
| US4466953A (en) * | 1979-08-14 | 1984-08-21 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix |
| US4492685A (en) * | 1979-08-14 | 1985-01-08 | Key Pharmaceuticals, Inc. | Protective skin matrix |
| US4470962A (en) * | 1979-08-14 | 1984-09-11 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix |
| US4438139A (en) | 1979-08-14 | 1984-03-20 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing estrogens |
| WO1983000093A1 (en) * | 1981-07-08 | 1983-01-20 | Key Pharma | Trinitroglycerol sustained release vehicles and preparation therefrom |
| WO1983000092A1 (en) * | 1981-07-08 | 1983-01-20 | Key Pharma | Polymeric diffusion matrix containing propranolol |
| WO1983000091A1 (en) * | 1981-07-08 | 1983-01-20 | Keith, Alec, Dell | Polymeric diffusion matrix containing 5-ad(3,4-dimethoxyphenethyl)methylaminobd-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile |
| US4460562A (en) * | 1982-01-06 | 1984-07-17 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US4482533A (en) * | 1982-01-11 | 1984-11-13 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing propranolol |
| US5278201A (en) * | 1988-10-03 | 1994-01-11 | Atrix Laboratories, Inc. | Biodegradable in-situ forming implants and methods of producing the same |
| US5702716A (en) * | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5990194A (en) * | 1988-10-03 | 1999-11-23 | Atrix Laboratories, Inc. | Biodegradable in-situ forming implants and methods of producing the same |
| US5632727A (en) * | 1988-10-03 | 1997-05-27 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
| US5739176A (en) * | 1988-10-03 | 1998-04-14 | Atrix Laboratories, Inc. | Biodegradable in-situ forming implants and methods of producing the same |
| US5733950A (en) * | 1988-10-03 | 1998-03-31 | Atrix Laboratories, Incorporated | Biodegradable in-situ forming implants and methods of producing the same |
| US5660849A (en) * | 1989-07-24 | 1997-08-26 | Atrix Laboratories, Inc. | Apparatus for forming a biodegradable implant precursor |
| US6395293B2 (en) | 1989-07-24 | 2002-05-28 | Atrix Laboratories | Biodegradable implant precursor |
| US6071530A (en) * | 1989-07-24 | 2000-06-06 | Atrix Laboratories, Inc. | Method and composition for treating a bone tissue defect |
| US5487897A (en) * | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
| USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
| US5462990A (en) * | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US5945115A (en) * | 1991-10-15 | 1999-08-31 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
| US5792469A (en) * | 1992-03-12 | 1998-08-11 | Atrix Laboratories, Inc. | Biodegradable in situ forming film dressing |
| US5681873A (en) * | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
| US5717030A (en) * | 1994-04-08 | 1998-02-10 | Atrix Laboratories, Inc. | Adjunctive polymer system for use with medical device |
| US5744153A (en) * | 1994-04-08 | 1998-04-28 | Atrix Laboratories, Inc. | Liquid delivery compositions |
| US5707647A (en) * | 1994-04-08 | 1998-01-13 | Atrix Laboratories, Inc. | Adjunctive polymer system for use with medical device |
| US5780044A (en) * | 1994-04-08 | 1998-07-14 | Atrix Laboratories, Inc. | Liquid delivery compositions |
| US5722950A (en) * | 1995-06-07 | 1998-03-03 | Atrix Laboratories, Inc. | Method for remote delivery of an aerosolized liquid |
| US6083524A (en) * | 1996-09-23 | 2000-07-04 | Focal, Inc. | Polymerizable biodegradable polymers including carbonate or dioxanone linkages |
| US6177095B1 (en) | 1996-09-23 | 2001-01-23 | Focal, Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages |
| USRE39713E1 (en) | 1996-09-23 | 2007-07-03 | Genzyme Corporation | Polymerizable biodegradable polymers including carbonate or dioxanone linkages |
| US7128927B1 (en) | 1998-04-14 | 2006-10-31 | Qlt Usa, Inc. | Emulsions for in-situ delivery systems |
| US6143314A (en) * | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
| US20040127846A1 (en) * | 1999-09-24 | 2004-07-01 | Dunn Richard L. | Coupling syringe system and methods for obtaining a mixed composition |
| US8226598B2 (en) | 1999-09-24 | 2012-07-24 | Tolmar Therapeutics, Inc. | Coupling syringe system and methods for obtaining a mixed composition |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20050152956A1 (en) * | 2000-08-30 | 2005-07-14 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US20110172196A1 (en) * | 2000-08-30 | 2011-07-14 | Dudley Robert E | Pharmaceutical composition and method for treating hypogonadism |
| US20110201586A1 (en) * | 2000-08-30 | 2011-08-18 | Dudley Robert E | Pharmaceutical composition and method for treating hypogonadism |
| US20050118242A1 (en) * | 2000-08-30 | 2005-06-02 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
| US9132089B2 (en) | 2000-08-30 | 2015-09-15 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040197302A1 (en) * | 2002-10-15 | 2004-10-07 | Porter Christopher H. | Prepolymeric materials for site specific delivery to the body |
| US20040157953A1 (en) * | 2002-10-15 | 2004-08-12 | Porter Christopher H. | Materials for filling cavities in the body |
| US20040156781A1 (en) * | 2002-10-15 | 2004-08-12 | Porter Christopher H. | Polymeric materials for site specific delivery to the body |
| US20070088012A1 (en) * | 2005-04-08 | 2007-04-19 | Woun Seo | Method of treating or preventing type-2 diabetes |
| US8466138B2 (en) | 2005-10-12 | 2013-06-18 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8486925B2 (en) | 2005-10-12 | 2013-07-16 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8729057B2 (en) | 2005-10-12 | 2014-05-20 | Unimed Pharmaeuticals, LLC | Testosterone gel and method of use |
| US8741881B2 (en) | 2005-10-12 | 2014-06-03 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8754070B2 (en) | 2005-10-12 | 2014-06-17 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8759329B2 (en) | 2005-10-12 | 2014-06-24 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8466136B2 (en) | 2005-10-12 | 2013-06-18 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| US8466137B2 (en) | 2005-10-12 | 2013-06-18 | Unimed Pharmaceuticals, Llc | Testosterone gel and method of use |
| WO2022155430A1 (en) * | 2021-01-15 | 2022-07-21 | Athena Devices, Inc. | Compositions and methods for soft tissue augmentation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2155658A (en) | Surgical and medical preparations | |
| DE60103894T2 (en) | Sprayable wound care compositions | |
| DE2852319C2 (en) | ||
| US4446578A (en) | Joint treatment | |
| RU2671837C2 (en) | Method for obtaining injectable hydrogel based on hyaluronic acid containing lidocaine added in powder form, and alkaline agent, sterilised with heat | |
| Miller | Cannula Implants and Review of Implantation Technics in Esthetic Surgery: In Two Parts | |
| US4185618A (en) | Promotion of fibrous tissue growth in fallopian tubes for female sterilization | |
| DE69524152T2 (en) | Sterile gel composition for wound treatment | |
| JPH01265970A (en) | Collagen water solution or water dispersion solution including hyaluronic acid | |
| BR112018009010B1 (en) | USE OF A SOL-GEL POLYMER COMPOSITE TO PREVENT OR TREAT MASTITIS IN A FEMALE NON-HUMAN MAMMALS THAT HAS A LACTATION PERIOD AND A SYSTEM FOR FORMING A PHYSICAL BARRIER IN THE TEAT CANAL OR CISTERNA OF SAID MAMMALS | |
| EP1735020A1 (en) | Injectable crosslinked and uncrosslinked alginates and the use thereof in medicine and in cosmetic surgery | |
| CN111317857A (en) | Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof | |
| CN111317858A (en) | A kind of degradable and absorbable bone hemostatic material and preparation method thereof | |
| KR20150022934A (en) | Method of preparing a composition based on hyaluronic acid | |
| DE69424147T2 (en) | Device for the vaginal administration of tamoxifen and its analogs | |
| WO1993002699A1 (en) | Use of collagen for the treatment of degenerative joint ailments | |
| AU2014271787A1 (en) | Adhesion preventing material | |
| EP0413418A2 (en) | Aqueous dispersions of polymers cross-linked with metallic ions | |
| EP0227656A1 (en) | Pharmaceutical compositions containing gels | |
| JPH0129774B2 (en) | ||
| WO2002040072A2 (en) | Filler composition for soft tissue augmentation and reconstructive surgery | |
| US2530480A (en) | Therapeutic preparations for intramuscular and subcutaneous injection and methods of making the same | |
| US2487975A (en) | Therapeutic preparations for intramuscular or subcutaneous injection and methods of making the same | |
| JP2004517655A (en) | How to repair fat bodies | |
| US20250127962A1 (en) | Gel comprising a hydrogel and fat or a fat derivative in the form of an emulsion |